Improving diagnosis in pleural mesothelioma Cancer
Conditions
Interventions
Current interventions as of 06/06/2025:
This is an observational study using historical data and stored samples from a multi-centre randomised controlled trial (TARGET
https://www.isrctn.com/ISRCTN14024829), where each participant will act as a case (additional tests applied to stored samples) and internal control (initial outcomes using standard testing only).
Ple
Sponsors
North Bristol NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients who were included in the TARGET trial (ISRCTN14024829). TARGET eligibility required all of the following to apply: 1. Pleural thickening on CT suspicious for pleural malignancy 2. Have had any form of pleural biopsy in the last 12 months (either by thoracoscopy or under radiological guidance) which was non-diagnostic for cancer 3. Lung cancer/mesothelioma MDT decision to perform further CT-guided biopsy to pursue a diagnosis
Exclusion criteria
Exclusion criteria: Not eligible if not recruited to the TARGET trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of malignancy on biopsy measured using immunohistochemistry (IHC) and fluorescent in-situ hybridisation (FISH) in the laboratory at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| The total number of biopsies required, time to diagnosis, stage at diagnosis, number of multi-disciplinary team (MDT) discussions, biopsy-associated costs, biopsy-related adverse events and survival measured using data recorded in medical records at one timepoint | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactGeraldine Lynch
Outcome results
None listed